Alnylam holds a 25-year biological delivery monopoly in GalNAc-siRNA gene silencing. HELIOS-B Phase 3 trial data expands their ATTR-CM addressable market by 6x. Subcutaneous 6-month dosing delivers recurring subscription-like 84%+ gross margin cash flows.

Exclusive global monopoly on Extreme Ultraviolet (EUV) lithography required for sub-3nm chip fabrication. High-NA EUV system shipments accelerating into 2026/2027 foundry expansion cycles.

Record free cash flow generation with spot gold trading above $2,600/oz against stagnant AISC production costs ($1,350/oz). Wyckoff Stage 2 markup expansion underway.